StockData
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. (KYMR) stock

KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30241% above fair value
$121.52−4.33 (-3.44%)

Close on Nov 17, 2026Market cap $10.37BP/E –Yield –

Kymera Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Kymera Therapeutics's enterprise value was $10.47B on Nov 11, 2026, against $4.36B a year earlier. Over the last 5 years it ranged from $278.83M to $10.47B, with a median of $1.74B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$10.47B+106.3%
2025Dec 31, 2025$5.08B+147.0%
2024Dec 31, 2024$2.05B+95.0%
2023Dec 29, 2023$1.05B+19.1%
2022Dec 30, 2022$884.69M-67.4%
2021Dec 31, 2021$2.72B+10.4%
2020Dec 31, 2020$2.46B–

More Kymera Therapeutics figures

See a number that looks wrong?